Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2015 On May 4, 2015

BOULDER, Colo., April 27, 2015 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2015 and hold a conference call to discuss those results on Monday, May 4, 2015.  Ron Squarer, Chief Executive Officer will lead the call.

Webcast, including Replay and Conference Call Slides:  http://edge.media-server.com/m/p/8tsxszuw/lan/en

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Six Phase 3 studies are currently enrolling patients. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca).  For more information on Array, please go to www.arraybiopharma.com.

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

SOURCE Array BioPharma Inc.

Related Links

http://www.arraybiopharma.com